• Nxera Pharma set forecasts for the year ending Dec. 31, 2026, at previous ranges' upper limits, with sales of JPY 48.8 billion.
• Core operating profit is forecast at JPY 22.8 billion; operating profit is projected at JPY 15.7 billion.
• The revision reflects a USD 100 million upfront payment under an exclusive global licensing agreement with AbbVie for its EP4 agonist program.
• Expected fourth-quarter revenue includes JPY 15.78 billion from the payment, using an exchange rate of JPY 157.8 per US dollar.
• The outlook assumes completion by year-end, subject to antitrust clearance, with revenue recognition dependent on agreement with auditors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.